Agilent Technologies to acquire Resolution Bioscience in $695m worth deal
Agilent Technologies, a US analytical instrumentation development and manufacturing company, has agreed to acquire Resolution Bioscience in a deal worth up to $695 million. Resolution ... Read More
ForDoz Pharma to manufacture LipoMedix’ oncology candidate Promitil
New Jersey-based ForDoz Pharma has signed an agreement with LipoMedix for manufacturing the latter’s lead compound - pegylated liposomal Promitil (PL-MLP) for a phase 2 ... Read More
Targovax’s ONCOS-102 receives FDA fast track designation for malignant pleural mesothelioma treatment
In a significant development for cancer treatment, Targovax, a Norwegian biotech firm specializing in immune-oncology, has announced that its lead candidate, ONCOS-102, has been granted ... Read More
FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb's Opdivo (nivolumab) and Exelixis' Cabometyx (cabozantinib) for the first-line ... Read More
AstraZeneca secures extended FDA approval for Tagrisso as adjuvant treatment in early-stage lung cancer
AstraZeneca has announced a significant breakthrough with the United States Food and Drug Administration (FDA) granting extended approval for its drug Tagrisso (osimertinib) as an ... Read More
Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
Boehringer Ingelheim has entered into a transformative €1.18 billion agreement to acquire NBE-Therapeutics, a clinical-stage biotech company based in Switzerland. This strategic acquisition is set ... Read More
PharmaEngine collaborates with Sentinel Oncology for cancer drug development
PharmaEngine, a Taiwanese pharmaceutical company, has entered a strategic collaboration and licensing agreement with UK-based Sentinel Oncology to accelerate the development of a promising new ... Read More
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the acquisition of VelosBio, a clinical-stage biopharmaceutical company ... Read More
CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer
US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological ... Read More
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More